Product Details
- Product Name: Axitinib Tablets
- Strengths: 1 mg and 5 mg
- Type: Authorized Generic version of INLYTA® (axitinib) tablets
- INLYTA® is a registered trademark of Pfizer Inc.
Market Context
According to IQVIA® sales data for the 12-month period ending September 2026, the U.S. annual sales of INLYTA® Tablets were approximately $538.4 million.
Strategic Rationale
Marc Kikuchi, President & Business Head, North America, stated that the launch reinforces Glenmark's commitment to expanding access to quality, affordable medicines for patients in the United States. He noted that adding this product strengthens the company's focus on addressing the evolving needs of patients and healthcare providers.